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See Article, pages 1398–1404Obesity and related metabolic disorders are prevalent and on
the rise in western countries, with limited therapeutic options.
Ursodeoxycholic acid (UDCA), is a widely used drug to treat liver
diseases including non-alcoholic fatty liver disease (NAFLD),
non-alcoholic steatohepatitis (NASH), cholestasis, and primary
biliary cirrhosis (PBC). Although UDCA treatment reduces hep-
atic steatosis and insulin resistance in mice [1], clinical evidence
supporting the mechanism of UDCA efﬁcacy on metabolic pro-
ﬁles in humans is lacking. In the paper titled ‘‘Ursodeoxycholic
acid exerts farnesoid X receptor-antagonistic effects on bile
acid and lipid metabolism in morbid obesity’’ Mueller et al.
[2], examined the effects of UDCA in a small cohort of mor-
bidly obese patients. By analysis of serum ﬁbroblast growth
factor 19 (FGF19), hepatic CYP7A1 expression and its product
7a-hydroxycholesterol in bile, they suggest that UDCA decreases
signaling of the nuclear receptor and ligand-activated transcrip-
tion factor farnesoid X receptor (FXR). Acute three-week treat-
ment with UDCA administered at 20 mg/kg/day, lowered
hepatic cholesterol and serum LDL-cholesterol, and induced
steroyl-CoA desaturase (SCD) resulting in an increase in less
toxic unsaturated fatty acids in the liver. This is the ﬁrst study
in humans reporting that inhibition of FXR signaling has ben-
eﬁcial effects for obesity.
Bile acids are synthesized in the liver from cholesterol by
cytochromes P450 (CYP) with CYP7A1 being the major, rate-
limiting enzyme. The oxidized bile acid metabolites are then
conjugated with glycine (mainly in humans) or taurine (mainly
in rats and mice) and then transported into the intestine. Bile
acids produced in the liver can be further metabolized by gut
bacteria through dehydroxylation and deconjugation reactions,
and most bile acids are then re-absorbed through the intestinal
epithelia to the blood stream, in the process of enterohepatic
circulation [3,4]. Bile acid synthesis and transport in the liver,
and transport in the intestine, is regulated by FXR. Some bile acidJournal of Hepatology 20
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they accumulate, can activate FXR resulting in down-regulation
of CYP7A1 and bile acid synthesis, decreased bile acid uptake
from the blood, and increased bile acid export to the canaliculus
and intestine, resulting in lower cellular bile acid levels. In
intestinal epithelial cells, activation of FXR increases bile acid
transport into the cell and to the blood followed by uptake by
the liver, thus completing the cycle of enterohepatic circulation.
In addition, FXR induces expression of the peptide hormone
FGF19 in the intestine that then activates the FGFR4/Klotho-b
receptor on the hepatocyte plasma membrane, which through a
signaling network, down-regulates CYP7A1 expression. Thus, in
the presence of high bile acid levels in the hepatocyte and intesti-
nal epithelial cells, FXR is activated, CYP7A1 is reduced, and bile
acid synthesis is suppressed. Some bile acid metabolites, notably
the conjugated derivatives, are FXR antagonists [5,6], and thus,
there likely exists a competition between FXR agonist and
antagonist for the modulation of this transcription factor and this
balance could inﬂuence metabolism and metabolic disorders in
mice and humans.
Due to the practical limitations in this human study of obesity
by Mueller et al., the precise mechanism of the effects of UDCA
could not be precisely determined, but the authors propose that
the efﬁcacy of this agent is due to suppression of FXR signaling.
Indeed, correlative evidence suggests that UDCA inhibits FXR sig-
naling and that this likely occurs in the intestine since levels of
FGF19 encoded by a FXR target gene in the intestine are
decreased about 20% and is correlated with an increase in
CYP7A1 expression. Hepatic FXR signaling did not appear to be
inﬂuenced by UDCA. Some of the beneﬁcial effects observed in
obesity are likely due to the increase in CYP7A1 as the authors’
suggest. Indeed, overexpression of human CYP7A1 in mice was
shown to have beneﬁcial metabolic effects, including decreased
high-fat diet-induced obesity and related insulin resistance
[7–10]. Three weeks of UDCA treatment in the study by Mueller
et al. might not be sufﬁcient to observe signiﬁcant differences
in insulin resistance. However, in another larger and longer
(1 year) randomized controlled trial, UDCA treatment improved
NASH and insulin resistance [11].15 vol. 62 j 1234–1236
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There are no published studies showing that UDCA is a direct
antagonist of FXR. To investigate this possibility at the in silico
level, molecular docking was used to investigate whether UDCA
can bind to the human FXR ligand-binding domain (LBD). The
FXR-LBD in complex with agonist 3d-chenodeoxycholic acid
(3dCDCA) was retrieved from the public database (1OT7, R1).
Initially, CDCA (7a-OH) was docked into the binding pocket with
a score of 42.8 reproducing the same non-covalent interactions
observedwith 3dCDCA (R1) plus the hydrogen bonds between the
3a-OH of the ligand and the side chain of residues His444 and
Tyr358 (Fig. 1A). UDCA (7b-OH) docked with a score of 38.96.
Interestingly, the b-OH isomerism at position C-7 of the ligand
does not favor formation of the hydrogen bond with both side
chains of Ser329 and Tyr366 previously detectedwith an FXR ago-
nist (Fig. 1A, B). The docking poses of CDCA and UDCA are similar
and primarily differ by the presence or not of the interaction
between the 7-OH of UDCA and Ser329 and/or Tyr366 of the pro-
tein. This could explain the weak antagonism or partial agonism
activity observed with this ligand. In any case, whether UDCA is
an FXR direct antagonist needs to be addressed experimentally.
After oral administration, UDCA is increased almost 50-fold
and thus it is surprising that it had no apparent effects on FXR
signaling in the liver, as monitored by the lack of a change in
the FXR target gene small heterodimer protein (SHP) mRNA
expression. This would also suggest that UDCA is not a direct
FXR antagonist. About 60% of the UDCA dose is absorbed in the
intestine, and over 60% of the absorbed dose enters the liver
and is readily conjugated with glycine to form gly-UDCA, and
to a lesser extent with taurine to form TUDCA [12]. The 20-fold
increase in serum TUDCA, could also contribute to the improved
metabolic effects, since TUDCA, is an inhibitor of ER stress [13]
that increases human insulin sensitivity [14].
Another possible contributor to the metabolic effects of UDCA
is changes in the composition of the gut microbiota. It is well
established that gut microbiota inﬂuences metabolic diseases
[15,16]. Perhaps an effect of UDCA on endogenous bile acid meta-
bolism as a result of elevated bile synthesis by CYP7A1 alters the
gut microbiota population and that this in turn inﬂuences meta-
bolism. In view of numerous correlative studies in humans and
mechanistic studies in mouse models, this possibility cannot be
excluded [5,6,17,18]. The altered bile acid composition from the
suppression of intestinal FXR by UDCA could generate agonist
for TGR5 and this signaling pathway may produce some of theA B
Fig. 1. Docking of CDCA (A) and UCDA (B) into the human FXR-LBD in the
agonist conformation (Molsoft ICM). The ligands are displayed as sticks and
colored by atom type, with carbon atoms in cyan (CDCA) and orange (UCDA);
protein residues are displayed as stick with the carbon atoms colored in green.
Secondary structure is displayed as ribbon. Protein–ligand hydrogen bond and
salt bridge interactions are displayed as dashed black lines, respectively (Molsoft
ICM).
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receptor (or GP-BAR1, M-BAR) is a G-coupled protein receptor
speciﬁc for bile acids that when activated, improves metabolic
disorders [19]. These possibilities require a more comprehensive
analysis of bile acid metabolites in subjects treated with UDCA. It
cannot be totally excluded that UDCA, or some UDCA metabolites
produced in vivo, modulates TGR5. Indeed, UDCA has TGR5 sig-
naling activity in reporter gene assays and was as a scaffold to
develop TGR5 activators [20–22].
FXR has emerged as a target for drugs to treat metabolic dis-
orders. The potent FXR agonist, obeticholic acid is in clinical trials
and has shown efﬁcacy for fatty liver disease and possibly for
insulin resistance [23]. Obeticholic acid targets the liver and sup-
presses bile acid synthesis and alters bile acid transport as noted
above resulting in lowering of cholestasis and hepatic lipids. A
recent study found that a gut-selective FXR agonist fexaramine
has beneﬁcial effects in high-fat diet-treated mice including
decreasing obesity and insulin resistance [24]. Other studies in
mouse models of obesity indicate that antagonism of intestinal
FXR signaling would be of potential clinical beneﬁc in the treat-
ment of obesity, insulin resistance and fatty liver disease [6,18].
These studies are in agreement with the human studies with
UDCA [2,11], yet additional clinical trials must be conducted to
determine if inhibition of intestinal FXR is a pathway for treat-
ment of human metabolic disorders.Conﬂict of interest
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